{'fraction_non_alphanumeric': 0.01689545934530095, 'fraction_numerical': 0.004223864836325237, 'mean_word_length': 5.91970802919708, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Suppression of activities of carbohydrate-metabolizing enzymes in adipose tissue of obese humans by clofibrate.

Abstract We studied the effects of insulin, epinephrine, and clofibrate on the activities of carbohydrate-metabolizing enzymes in adipose tissue of 8 obese human volunteer subjects. In all patients, clofibrate decreased the activities of pyruvate kinase, phosphofructokinase, fructose diphosphate aldolase, and fructose diphosphatase after 7 days of treatment. In 4 patients studied in more detail, insulin produced a significant increase in pyruvate kinase and phosphofructokinase activities and a significant decrease in fructose diphosphatase within 5 minutes. Epinephrine injection produced opposite effects. Clofibrate decreased these responses to both insulin and epinephrine. Clofibrate may act at the plasma membrane of the adipose cell to inhibit the lipolytic effects of epinephrine and the antilipolytic effects of insulin.